Stereotactic ablative radiotherapy (SABR) for treatment of central and ultra-central XXXX .

@entity1 @entity662 @entity137 @entity1263 @entity55 @entity5 @entity2
OBJECTIVES: Treatment of central and ultra-central @entity2 with stereotactic ablative radiotherapy (SABR) remains controversial due to risks of treatment-related @entity137 compared with @entity1263 . Here we report our institution's experience in treating central and ultra-central @entity2 @entity1 with SABR. MATERIALS AND METHODS: We retrospectively reviewed outcomes in 68 @entity1 with @entity2 , 34 central and 34 peripheral, all treated with SABR consisting of 50Gy in 4-5 fractions. @entity5 centrality was defined per the RTOG 0813 protocol. We defined "ultra-central" @entity5 as those with GTV directly abutting the central airway. RESULTS: Median follow-up time was 18.4months and median overall survival was 38.1 months. Two-year overall survival was similar between ultra-central, central, and peripheral NSCLC (80.0% vs. 63.2% vs. 86.6%, P=0.62), as was 2-year local failure (0% vs. 10.0% vs. 16.3%, P=0.64). @entity137 rates were low and comparable between the three groups, with only two cases of grade 3 @entity137 ( @entity662 ), and one case of grade 4 @entity137 ( @entity55 ) observed. @entity1 with ultra-central @entity5 experienced no symptomatic @entity137 over a median follow-up time of 23.6 months. Dosimetric analysis revealed that RTOG 0813 central airway dose constraints were frequently not achieved in central @entity5 treatment plans, but this did not correlate with increased @entity137 rate. CONCLUSION: @entity1 with central and ultra-central @entity2 treated with SABR (50Gy in 4-5 fractions) experienced few @entity137 and good outcomes, similar to @entity1 with @entity1263 .
